Business
NovAccess Global Announces Fireside Chat with Dr. Christopher Wheeler, the Company’s Lead Scientist and President of its StemVax Therapeutics Division
NovAccess Global Announces Fireside Chat with Dr. Christopher Wheeler, the Company’s Lead Scientist and President of its StemVax Therapeutics Division.
About this update from Novaccess Global Inc.
[{"type":"text","content":"Topic: Immunotherapy Advantages Over Surgical TreatmentCLEVELAND, OH / ACCESSWIRE / January 5, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the availability of its latest monthly installment in a series of fireside chat interviews, with additional sessions to be made available as company developments arise. Interviews are intended to cover important and timely topics relating to the Company, its platform technologies and the global healthcare and business environments.The fireside chat announced today is an interview conducted by J. Kyle Moyer, the host of Biotech Novelty, an online media brand created to serve as a platform to discuss biotech healthcare innovations, with Dr. Christopher Wheeler, Ph.D., President, StemVax Therapeutics Inc., a division of NovAccess Global and the lead scientist for the Company. NovAccess Global's CEO Dr. Dwain Irvin also participated in the session. The interview is being streamed for public viewing over the Internet and can be accessed via the News tab of the Investors section of the NovAccess Global website at https://novaccessglobal.com/news/, on all of the Company's social media feeds, and on the Biotech Novelty website/social media feeds.During the interview made available today, the speakers highlight:TLR-AD1 as a therapy at the Investigational New Drug (IND) filing stage, with StemVax Therapeutics seeking to start human clinical trials after obtaining IND approvalThe Company's patented technology, TLR-AD1, is a novel, highly-focused immunotherapeutic approach to better equip the patient's own immune cells to recognize and kill cancer cellsIn October 2022, NovAccess announced the approval of its application with the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation (ODD) for TLR-AD1Potential access to non-dilutive funding and regulatory guidance from ODD designationThe Company's differentiated approach to the treatment of aggressive braincancers, including glioblastoma and other high-grade gliomasDr. Wheeler's belief that NovAccess Global is "ahead of the curve" in brain tumor therapies, and addresses his work with dendritic cells (special types of cells that are found in tissue which boosts immune responses by revealing antigens)Origins of NovAccess Global biotechnology...